AVIR Green Hills reaches important Milestone


AVIR Green Hills Biotechnology AG is testing the trivalent influenza vaccine deltaFLU in a phase I/II study at the Medical University Vienna. This is a very important milestone referring to the development of innovative intranasal influenza vaccines. The formulation of the vaccine consists of three virus strains (H1N1, H3N2 and B) and is similar to the composition of the final product. The phase I/II study of deltaFLU will close in the middle of September 2011 and data will be expected in October/November 2011. Dr. Thomas Muster, CEO/CSO of AVIR Green Hills:”We are very enthusiastic and satisfied that the safety profile of the vaccine deltaFLU was confirmed again and we are looking forward to the study results”

The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)lisavienna.at.